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BACKGROUND: We address the prognostic and predictive value of KRAS, PIK3CA and BRAF mutations for clinical outcomes in response
to active agents in the treatment of metastatic colorectal cancer (mCRC).
METHODS: We determined KRAS, BRAF and PIK3CA mutations in tumours from 168 patients treated for mCRC at two institutions.
All patients received 5-FU-based first-line chemotherapy and treatment outcome was analysed retrospectively.
RESULTS: KRAS, BRAF and PIK3CA mutations were present in 62 (37%), 13 (8%) and 26 (15%) cases, respectively. Multivariate analysis
uncovered BRAF mutation as an independent prognostic factor for decreased survival (hazard ratio (HR) 4.0, 95% confidence interval
(CI) 2.1–7.6). In addition, patients with BRAF-mutant tumours had significantly lower progression-free survival (PFS: HR 4.0, 95%
CI 2.2–7.4) than those whose tumors that carried wild-type BRAF. Among 92 patients treated using chemotherapy and cetuximab as
salvage therapy, KRAS mutation was associated with lack of response (P¼0.002) and shorter PFS (P¼0.09). BRAF (P¼0.0005) and
PIK3CA (P¼0.01) mutations also predicted reduced PFS in response to cetuximab salvage therapy.
CONCLUSIONS: These results underscore the potential of mutational profiling to identify CRCs with different natural histories or
treatment responses. The adverse significance of BRAF mutation should inform patient selection and stratification in clinical trials.
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Combinatorial and sequential administration of 5-fluorouracil
(5-FU), oxaliplatin and irinotecan has substantially increased the
overall survival (OS) in metastatic colorectal cancer (mCRC),
although treatment goals remain primarily palliative (Grothey
et al, 2004). Monoclonal antibodies (mAb) bevacizumab, against
the vascular endothelial growth factor (VEGF) receptor, and
cetuximab or panitumumab, against the epidermal growth factor
receptor (EGFR), expand treatment options and further improve
progression-free (PFS) and OS (Cunningham et al, 2004; Hurwitz
et al, 2004; Van et al, 2007).
The genetic underpinnings of colorectal cancer (CRC) are
especially well characterized (Vogelstein and Kinzler, 2004) and
include common somatic mutations in the APC, TP53 and KRAS
genes, followed in frequency by PIK3CA and BRAF mutations
(Wood et al, 2007). Activating mutations in the KRAS, BRAF and
PIK3CA oncogenes deregulate growth-factor pathways, stimulate
cell proliferation and promote metastasis (Huang et al, 2007;
Schubbert et al, 2007). Presence of KRAS mutations in primary
CRC portends a poor response to monotherapy and combination
therapy using anti-EGFR mAB cetuximab or panitumumab
(Amado et al, 2008; Karapetis et al, 2008; Lievre et al, 2008). In
one study that included few patients with stage IV disease and
BRAF mutations, the latter were associated with limited survival in
patients with microsatellite-stable (MSS) disease (Samowitz et al,
2005); mutations in exons 9 or 20 of the PIK3CA gene are
associated with lower relapse-free survival in patients with stage II
or III CRC (Kato et al, 2007). These data notwithstanding, there is
limited understanding of the extent to which common KRAS,
BRAF and PIK3CA mutations influence clinical outcomes in
patients with mCRC treated with chemotherapy and/or biological
therapy. Treatments are selected largely without regard for tumour
mutation profiles, although recent evidence linking KRAS muta-
tion with poor response to EGFR mAb (Amado et al, 2008;
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sKarapetis et al, 2008; Lievre et al, 2008) now influences decisions in
the clinic.
We postulated that mutations in some of these oncogenes would
correlate with overall prognosis and with treatment outcomes in
patients receiving different regimens. To test these hypotheses, we
first evaluated the prognostic significance of KRAS, BRAF and
PIK3CA mutations in a cohort of patients with mCRC, treated
using 5FU-based chemotherapy. Using a uniform catalogue of
retrospective but detailed clinical information, we then tested the
predictive value of these mutations on patient outcomes after
treatment using the most common therapeutic regimens.
MATERIALS AND METHODS
Patients and study design
Tumour samples were collected from patients with histologically
confirmed mCRC, treated at two centers, Dana-Farber/Partners
Cancer Care (Boston, MA, USA) and University Hospital of
Heraklion (Heraklion, Crete, Greece), between January 2004 and
March 2007. All patients who gave informed consent and whose
colectomy samples were available for molecular analysis were
included in the analysis, without further selection. Failure to
participate in the tumour registry was unusual, and the cohort
essentially represents consecutive patients with mCRC who were
treated at the two academic centres and gave informed consent for
molecular analysis of DNA from the primary tumour. Institutional
ethics committees approved the study.
First-line and salvage regimens, selected at the discretion of the
treating physician, followed common practices in mCRC (sum-
marized in Table 1). Patients were evaluated at baseline and after
every four cycles of therapy, with occasional variation, as clinically
indicated, during the treatment. Disease status was coded, without
the knowledge of the mutational profile, after retrospective review
of physician notes and reports of staging radiographs, including
tumour measurements; efficacy was assessed on an intent-to-treat
basis. Disease progression was defined as the appearance of any
new lesion or a greater than 20% increase in the sum of the longest
diameter (LD) of target lesions, extracted from radiology reports,
and taking as reference the lowest value recorded in the treatment
period. Response toward cetuximab was defined as the reduction,
by at least 30%, in the sum of the LD of target lesions compared
with the baseline sum.
Specimen Characteristics and Assay Methods
Formalin-fixed, paraffin-embedded tumour sections were reviewed
by pathologists to confirm the diagnosis and define tumour-
enriched areas for dissection. From each paraffin block of
representative tumour areas, we stained 10 serial sections of
8mm thickness with nuclear fast red (Sigma-Aldrich, St Louis, MO,
USA) and isolated malignant cells by scrape dissection under a
binocular microscope. Macrodissected cells were lysed in buffer
containing Proteinase K (Puregene, Gentra Systems, Minneapolis,
MN, USA) at 601C for 72h, followed by DNA extraction according
to the manufacturer’s protocol.
Mutations were detected in the Dana-Farber sample set by
Sequenom mass-spectrometric genotyping (Thomas et al, 2007)
after whole-genome amplification by PCR, and in the Heraklion
samples by Sanger sequencing after PCR amplification of KRAS
exon 2, BRAF exon 15, and PIK3CA exons 9 and 20. PCR
conditions and the primers used to amplify specific exons are
listed in Supplementary Table 1. Results from the two different
methods for detecting mutations were cross-confirmed on the
other platform, along with positive and negative controls.
Statistical analysis
Associations between treatment response and mutation status or
baseline characteristics were assessed using the Fisher’s exact test
for dichotomous variables, or logistic regression for continuous
variables. PFS was measured from the last radiographic study
before the initiation of first-line therapy to the first radiographic
documentation of disease progression or death, and OS was
calculated from the date of diagnosis of metastatic disease to death
due to any cause. For cetuximab treatment, PFS was calculated
from the date of documented progression after the previous
treatment to the next documentation of disease progression or
death. Kaplan–Meier curves were used to describe the proportion
of patients who remained free of events over the follow-up period.
Associations between prognostic factors and PFS or OS were
examined using Cox proportional hazards regression models; we
report hazard ratio (HR) estimates and their 95% confidence
intervals (CI).
We used Cox regression models with interaction terms to assess
whether mutational effects varied across treatment subgroups. For
each mutation, three hypotheses were tested: (1) whether effect on
first-line PFS varied according to regimen (oxaliplatin based,
irinotecan based or both); (2) whether the effect on first-line PFS
varied according to inclusion or exclusion of bevacizumab; and
(3) whether the effect on PFS for cetuximab varied according to the
line of treatment (first vs Xthird). All reported P-values are two-
sided and not adjusted for multiple testing.
RESULTS
Patient and tumour characteristics, treatments and clinical
outcomes
We determined with confidence the mutational status for KRAS
exon 2, BRAF exon 15, and PIK3CA exons 9 and 20 in 168
consecutive patients with mCRC, for whom a representative
sample from the primary tumour was available for molecular
analysis of DNA. Disease characteristics were typical for mCRC in
North America and Europe (Table 2), and patients were treated
according to prevailing practice patterns (Table 1). KRAS
mutations were detected in 62 (37%), BRAF mutations in 13
(8%) and PIK3CA mutations in 26 (15%, 18 in exon 9 and 8 in exon
20) primary tumours, respectively. Seven tumours carried both
KRAS and PIK3CA mutations, whereas BRAF mutations did not
co-occur with the others; these frequencies closely match those in
published reports (Wood et al, 2007) and were similar between the
Table 1 Treatment regimens used in this retrospective study
First-line regimens N (out of 168) %
FOLFOX+bevacizumab 76 45
FOLFIRI+bevacizumab 19 11
5FU+bevacizumab 2 1
FOLFOX+cetuximab 8 5
FOLFOXIRI 17 10
FOLFIRI 25 15
FOLFOX 16 10
5FU only 5 3
Oxaliplatin-based treatment (first line) 100 60
Irinotecan-based treatment (first line) 44 26
Bevacizumab+chemotherapy (first line) 97 58
Oxaliplatin-based treatment (any line) 144 86
Irinotecan-based treatment (any line) 121 72
Bevacizumab+chemotherapy (any line) 131 78
Cetuximab+chemotherapy (any line) 100 60
Patients treated with all three chemotherapy drugs 106 63
Patients treated with all five active agents 87 52
FOLFIRI¼Folinic acid, 5FU, irinotecan; FOLFOX¼Folinic acid, 5FU, oxaliplatin;
FOLFOXIRI¼Folinic acid, 5FU, oxaliplatin, irinotecan.
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sUS and Greek cohorts (Supplementary Table 2). Mutations in any
gene did not correlate significantly with patient gender or age,
stage at diagnosis, or histological grade (all P-values 40.05). As
patient characteristics, mutation frequencies and treatment regi-
mens were all typical for CRC, the results of our analysis should
serve as a useful guide for clinical practice.
The median time from initial diagnosis to diagnosis of
metastatic disease was 18.4 months (95% CI 14.4–20.4) for
patients with stage I–III disease at presentation and 0.6 months
(95% CI 0.1–1.4) for patients classified with stage IV disease. The
median time from the last radiological assessment to the initiation
of first-line chemotherapy was 0.6 months (95% CI 0.4–0.8),
whereas median duration from the diagnosis of metastatic disease
was 1.2 months (95% CI 0.9–1.3).
OS was similar between the two participating centres (median
38.9 months, 95% CI 33.4–46.3 months) and higher than other
published values (Grothey et al, 2004; Hurwitz et al, 2004).
Considering that patients were not selected on the basis of
performance status or other clinical criteria, one possibility for
improved outcomes may be that after initial response to systemic
treatment, 30 out of 50 patients with solitary metastases
(representing 18% of the total cohort) had metastases resected.
Response to particular agents was, however, monitored in all
patients and we examined the role of metastatectomy as a variable.
Univariate analysis (Table 2) showed significant associations of OS
with age 465 years (P¼0.03), undifferentiated (grade 3) primary
tumours (P¼0.02), colonic vs rectal location (P¼0.02), solitary
metastasis (P¼0.008) and BRAF mutations (Po0.0001, Figure 1).
When all factors significant in univariate analysis were subjected
to multivariate analysis (Table 3), only BRAF mutation remained
as an independent prognostic factor for reduced OS (HR 4.0, 95%
CI 2.1–8.0).
Table 2 Characteristics of enrolled patients and univariate analysis for survival
First-line progression-free survival Overall survival
Feature N %
Median
(months) HR (95% CI) P-value
Median
(months) HR (95% CI) P-value
Median age (range) 59 (23–86) 1.1 (0.8–1.6) 0.5 1.7 (1.1–2.6) 0.03
p65 years 113 67 12.5 43.7
465 years 55 33 10.7 30.6
Gender 1.1 (0.8–1.5) 0.8 1.0 (0.7–1.6) 0.8
Male 87 52 11.7 38.9
Female 81 48 12.5 38.2
Stage at diagnosis
I–III 77 46 13.6 0.8 (0.6–1.1) 0.2 38.2 1.2 (0.8–1.8) 0.5
IV 91 54 11.6 35.2
Tumour location
Colon 135 80 11.3 1.8 (1.2–2.7) 0.008 33.5 2.0 (1.1–3.7) 0.02
Rectum 33 20 16.3 66.6
Number of metastatic lesions Median: 2
1 50 30 20.5 0.4 (0.2–0.6) o0.0001 56.8 0.4 (0.2–0.8) 0.008
2 83 49 11.7 0.8 (0.5–1.2) 0.2 34.8 0.8 (0.5–1.4) 0.4
X3 35 21 10.5 28.8
Number of treatment lines Median: 3
1 43 25 44.5 0.3 (0.2–0.5) o0.0001 35.2 1.6 (0.9–2.8) 0.1
2 47 28 11.5 0.9 (0.6–1.3) 0.7 34.8 1.4 (0.8) 0.2
X3 78 47 11.8 39.1
Histologic grade 1.4 (1.0–2.1) 0.06 1.8 (1.1–2.8) 0.02
I–II 127 76 12.5 41.1
III 41 24 9.4 33.7
Adjuvant treatment 1.1 (0.8–1.6) 0.6 1.0 (0.7–1.6) 0.9
Yes 58 35 13.7 38.9
No 110 65 11.7 39.1
Metastatectomy 0.4(0.2–0.6) o0.0001 0.6 (0.3–1.2) 0.1
Yes 30 18 27.4 46.3
No 138 82 11.1 38.4
KRAS status 0.9 (0.7–1.3) 0.7 1.1 (0.7–1.8) 0.6
Mutant 62 37 12.3 35.8
WT 106 63 11.8 40.5
BRAF status 4.9 (2.7–9.0) o0.0001 4.5 (2.4–8.4) o0.0001
Mutant 13 8 4.3 10.9
WT 155 92 12.5 40.5
PIK3CA status 1.3 (0.8–1.9) 0.3 1.0 (0.6–1.8) 0.99
Mutant 26 15 11.4 44.7
WT 142 85 12.1 38.2
HR¼hazard ratio; WT¼wild type.
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chemotherapy
Combination chemotherapy was administered in the first line in
161 patients (96%), with or without mAb supplementation
(Table 1); 5 patients (3%) received 5-FU as the only cytotoxic
agent. One hundred patients (60%) were treated with the folinic
acid–fluororuracil–oxaliplatin (FOLFOX) regimen, with or with-
out the addition of a mAb, in the first line and 97 patients (58%)
received bevacizumab in addition to fluoropyrimidine-based
chemotherapy; a smaller fraction, 24% (44 patients) was treated
with irinotecan in the first line. Seventeen patients (10%) received
both oxaliplatin and irinotecan (Table 1). In all, 106 patients (63%)
received all three active chemotherapy drugs and 87 patients (52%)
received all five active agents at some point in their disease course.
KRAS or PIK3CA mutations did not influence PFS after first-line
therapy (Figure 2). In contrast, patients with BRAF-mutant
tumours had significantly lower PFS (median 4.3 vs 12.5 months;
Po0.0001) compared with patients whose primary tumours
carried only wild-type (WT) BRAF alleles (Figure 2). The
association between BRAF mutation and reduced PFS (HR 4.9,
95% CI 2.7–9.0) after first-line therapy (Table 3) was similar for
patients receiving oxaliplatin-, irinotecan- or both (interaction test
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BRAF WT       40.5 (35.2−47.7)
BRAF mutant 10.9 (8.0–18.3)
Median 95% CI
KRAS WT       40.5 (31.0−51.8)
KRAS mutant  35.8 (30.6–54.7)
Median 95% CI
P−value < 0.0001; HR=4.5
01 2
621100
24 36 48 60 72
BRAF WT: 155
BRAF mutant: 13
P−value = 0.6; HR=1.1
PIK3CA WT       38.2 (31.7−46.3)
PIK3CA mutant  44.7 (29.3–55.6)
Median 95% CI
P−value = 0.99; HR=1.0
Months
137 94 43 18 8 3
01 2
54 33 14 6 1 1
24 36 48 60 72
BRAF WT: 106
BRAF mutant: 62
89 63 30 13 7 2
01 2
23 9 9 5 0 0
24 36 48 60 72
PIK3CA WT: 142
PIK3CA mutant: 26
120 78 35 14 8 3
Figure 1 Overall survival after the diagnosis of metastatic disease, analysed by mutation status.
Table 3 Results of multivariate analysis for progression-free and overall
survival
Hazard ratio 95% CI P-value
Progression-free survival
BRAF (mutant vs WT*) 4.0 (2.2, 7.4) o0.0001
Age (465 vs p65 years) 1.4 (1.0, 2.0) 0.06
Tumour grade (3 vs 1–2) 1.5 (1.0, 2.2) 0.06
Metastatectomy (yes vs no) 0.6 (0.4, 1.1) 0.08
Tumour location (colon vs rectum) 1.6 (1.0, 2.4) 0.05
Number of treatment lines (1 vs 43) 0.3 (0.2, 0.5) o0.0001
Number of treatment lines (2 vs 43) 0.9 (0.6, 1.3) 0.5
Overall survival
BRAF (mutant vs WT) 4.1 (2.1, 8.0) o0.0001
Age (465 vs p65 years) 1.5 (1.0, 2.4) 0.07
Tumour grade (3 vs 1–2) 1.3 (0.8, 2.1) 0.3
Metastatectomy (yes vs no) 0.6 (0.3, 1.3) 0.2
Stage at diagnosis (I–III vs IV) 1.3 (0.8, 2.0) 0.2
Tumor location (colon vs rectum) 1.8 (0.9, 3.3) 0.08
Number of lines of treatment (1 vs X3) 1.8 (0.98, 3.3) 0.06
Number of lines of treatment (2 vs X3) 1.4 (0.8, 2.3) 0.3
CI¼confidence interval; WT¼wild type.
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without bevacizumab (interaction test P¼0.8). Specifically, BRAF
mutation predicted more rapid disease progression in patients
treated with first-line oxaliplatin- (HR 6.4, 95% CI 2.6–15.6),
irinotecan- (HR 4.1, 95% CI 1.5–11.3), or oxaliplatin and
irinotecan (HR 7.9, 95% CI 1.3–48.2), as well as bevacizumab-
containing (HR 5.1, 95% CI 2.4–11.1) regimens (Supplementary
Table 3). Thus, KRAS and PIK3CA mutations did not show
predictive value with respect to cytotoxic agents and our
observations single out BRAF mutation in the primary tumour
as an adverse factor, independent of the first-line treatment.
Impact of mutation status on the outcome of salvage
cetuximab therapy
One hundred patients were treated with cetuximab, 8 in the first
line, 37 in the second and 55 in the third or higher, always in
combination with chemotherapy. All patients receiving cetuximab
in the second or subsequent line were refractory to previous
regimens. Restricting analysis to the 92 patients who received
cetuximab combinations as salvage therapy, none of the 32
patients with a KRAS-mutant tumour responded to treatment,
whereas objective responses occurred in 14 of 60 (23%) patients
whose tumors harboured only WT KRAS alleles (P¼0.002). This
striking difference confirms the results from prospective trials of
cetuximab or panitumumab monotherapy (Amado et al, 2008;
Karapetis et al, 2008; Lievre et al, 2008) and validates our approach
to identify associations to guide the treatment of mCRC. It should
be noted that none of the 9 patients with a BRAF-mutant tumour
responded to cetuximab, whereas objective responses occurred in
14 of 83 (17%) patients whose tumours carried WT BRAF alleles.
Presence of PIK3CA mutations showed no correlation with
objective tumour responses to cetuximab. PFS was significantly
lower among patients whose tumours carried mutations in BRAF
(2.0 vs 3.9 months, HR 3.6, 95% CI 1.8–7.4), PIK3CA (2.5 vs 3.9
months, HR 2.1, 95% CI 1.2–3.9) or any of the three genes (2.5 vs
6.4 months, HR 2.1, 95% CI 1.3–3.2), and marginally lower in
patients with KRAS-mutant tumours (2.5 vs 4.8 months, HR 1.5,
95% CI 0.9–2.3), compared with patients whose primary tumors
were wild type at each locus (Figure 3, Supplementary Table 3).
Importantly, patients whose tumour had BRAF or PIK3CA
mutation had shorter PFS regardless of whether cetuximab was
administered in the second, or third and higher lines (interaction
tests P¼0.5 and 0.6, respectively). Thus, the lack of EGFR mAb
response observed in the setting of mutant KRAS (Schubbert et al,
2007; Amado et al, 2008) extends to other common mutations that
deregulate cellular signalling pathways, especially BRAF and
probably even PIK3CA. Lower PFS did not translate into
differences in OS between patients with WT or mutant KRAS
and PIK3CA alleles in the primary tumour.
DISCUSSION
Among the many genetic alterations in CRC, particular point
mutations in three oncogenes, KRAS, PIK3CA and BRAF, occur at
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BRAF WT         12.5    (11.6−14.7)
BRAF mutant   4.3      (3.5–9.8)
Median     95% CI
KRAS WT         11.8    (10.8−13.7)
KRAS mutant    12.3    (10.5–17.0)
Median     95% CI
P−value < 0.0001; HR=4.9
01 2
1000
24 36 48
BRAF WT: 155
BRAF mutant: 13
P−value = 0.69; HR=0.9
PIK3CA WT         12.1    (11.0−14.4)
PIK3CA mutant    11.4    (9.0–17.0)
Median     95% CI
P−value = 0.30; HR=1.3
Months
80 27 8 1
01 2
32 9 3 1
24 36 48
KRAS WT: 106
KRAS mutant: 62
49 18 5 0
01 2
12 4 1 0
24 36 48
PIK3CA WT: 142
PIK3CA mutant: 26
69 23 7 1
Figure 2 Progression-free survival after first-line chemotherapy, analysed by mutation status.
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esis and as targets for molecular therapy (Wood et al, 2007). Each
of these targets is the subject of intense drug development efforts.
Appreciation of the predictive significance of underlying oncogene
mutations will aid in design of clinical trials of new agents,
administered either alone or in combination with other drugs, and
in interpreting results from new and old trials. Moreover, current
treatment approaches toward mCRC rarely consider biological
properties associated with individual mutations, mainly because
there is a paucity of information about the influence of specific
mutations on natural history or the response to particular
treatments. We report the results of retrospective investigation
designed to help define the role of tumour mutation profiles in the
management of patients with mCRC. Even though treatment
choices and staging studies were not dictated by a strict clinical
trial, the results are robust and relate well to current treatment
paradigms.
A principal finding was that BRAF mutation the primary tumour
marks patients who carry an especially poor prognosis, regardless
of specific treatment regimen. Compared with patients with
BRAF
WT tumours, those with BRAF
MUT tumours have significantly
higher likelihood of disease progression (Po0.0001) or death
(Po0.0001) with any current regimen (Table 3); the BRAF V600E
mutation predicted independently for early relapse on first-line
therapy (HR 4.0, 95% CI 2.2–7.4) and death (HR 4.0, 95%
CI 2.1–8.0). These data warrant confirmation and should provoke
thoughtful consideration of the risks and benefits of administering
5-FU, oxaliplatin or irinotecan in such patients, who should
probably also be considered as a distinct group by stratification in
future clinical trials. The poorer PFS with first-line therapy
suggests that BRAF mutation could be prognostic, predictive or
both. As this association was highly significant for patients
receiving oxaliplatin, irinotecan or both, as well as for patients
receiving bevacizumab or not, the conservative interpretation is
that BRAF mutation is a prognostic rather than a predictive
marker.
Our observations have interesting implications for pathogenic
mechanisms and disease subgroups. Activating mutations in both
KRAS and BRAF stimulate the MEK or extracellular signal-
regulated kinase–microtubule-associated protein (ERK–MAP)
kinase cascade (Vogelstein and Kinzler, 2004). As the two
mutations tend to be mutually exclusive (Rajagopalan et al, 2002;
Yuen et al, 2002), KRAS is inferred to signal principally through
BRAF in colon cancer cells, leading to an assumption that tumours
with KRAS or BRAF mutations may be equally vulnerable to
inhibition of BRAF. Our finding that the natural history and
treatment response of BRAF-mutant tumours differ markedly from
all others implies that BRAF mutation does not simply substitute
for KRAS activation in a linear signalling pathway but probably
confers additional or distinct properties, with ominous conse-
quences. In cultured cells, the V600E mutation increases BRAF
activity independent of KRAS and shows lower transforming
activity than oncogenic KRAS (Davies et al, 2002). Likewise, small-
molecule inhibition of MEK abrogated tumour growth more
profoundly in BRAF-mutant than KRAS-mutant tumour xeno-
grafts (Solit et al, 2006). Such differences may in part underlie the
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Figure 3 Progression-free survival after salvage cetuximab therapy in 92 patients, analysed by mutation status.
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scontrast in predictive value of activating KRAS and BRAF
mutations. Second, the frequency of BRAF mutation is especially
high, up to 50%, in tumours with microsatellite instability (MSI
hi)
(Rajagopalan et al, 2002), which otherwise carry a favourable
prognosis (Popat et al, 2005). If the outcome of patients with BRAF
mutation is so poor, then the natural history of MSI
hi tumours
lacking BRAF mutation must be even more favourable; a recent
study of patients with operable stage II or stage III CRC made the
same suggestion (French et al, 2008). If this idea is confirmed,
patients with such tumors may, in the future, be candidates for
prolonged observation without treatment.
In agreement with recent reports (Bokemeyer et al, 2008; Van
Cutsem et al, 2009), mutant or WT status for KRAS did not
correlate with the outcomes in patients treated with front-line
5FU-based regimens. Although a previous study reported worse
outcomes in patients with early (stages II–III) PIK3CA-mutant
CRC (Kato et al, 2007), the aggregate data do not currently suggest
that KRAS-o rPIK3CA-mutant tumours have distinctive clinical
profiles or differential response to currently approved chemother-
apy. The lack of overall predictive significance of KRAS mutation
despite its effect on cetuximab treatment hints that the adverse
effect of BRAF mutation is not explained just by the limited
response to cetuximab.
This study reinforces the value of mutational analysis in patients
treated with EGFR mAb. Patients with KRAS-mutant tumours
treated with cetuximab in any combination had lower PFS
compared with those with KRAS
WT tumours, results that extend
those reported in recent clinical trials (Bokemeyer et al, 2008; Van
Cutsem et al, 2009) and suggest that KRAS mutation may bypass
aberrant EGFR signalling. We observed similar trends in the
likelihood of response between patients with BRAF-mutant or
BRAF
WT tumours (0 vs 17%). Although responses in PIK3CA-
mutant cases were not clearly as worse as they were in cases with
KRAS or BRAF mutation, PFS with cetuximab-based therapy was
significantly lower when tumors carried mutations in any of the
three examined genes, and both BRAF (HR 3.9, P¼0.0005) and
PIK3CA (HR 2.1, P¼0.01) mutations conferred higher risk of
relapse after treatment with cetuximab-containing salvage combi-
nations. Two studies that previously considered the significance of
BRAF and PIK3CA mutations in treatment response to anti-EGFR
mAb (Moroni et al, 2005; Lievre et al, 2006) had small sample sizes
(30 and 31 cases, fewer than three with mutations). Our study
extends the current paradigm to imply that patients with KRAS-,
BRAF-o rPIK3CA-mutant tumours may all derive limited benefit
from treatment with EGFR mAb, and that BRAF mutations in
particular account for a measurable fraction of patients
whose KRAS
WT tumours do not respond to cetuximab. Reduced
PFS in PIK3CA-mutant mCRC is not simply a function of
poorer prognosis because overall outcomes are unrelated to this
genetic event (Figure 1). Indeed, KRAS and PIK3CA mutations
were not associated with worse OS, possibly because 82% of
patients received another regimen after progression on cetuximab-
based treatment or because response to cetuximab impacts
modestly on the natural history of mCRC. (Messersmith and
Ahnen, 2008).
Colorectal tumours are typically accessible for molecular
characterization and common mutations localize in specific exons.
Although it is formally possible that the mutational profile of
metastatic deposits differs from that in the primary tumour, recent
analyses indicate that this is not the case, (Jones et al, 2008); in any
event, our analysis shows certain molecular lesions in the
primary tumor as markers of the clinical outcome in mCRC. As
we studied a large number of unselected cases with good
representation of index mutations, the results are robust and
directly relevant to current management of mCRC. They advance
application of CRC mutation profiles to define patient sub-groups
and should influence patient selection or stratification for
prospective trials. KRAS and PIK3CA mutations seem not to be
useful predictors for response to current treatment regimens. If
our conclusions are confirmed independently, then patients with
the BRAF V600E mutation might justify foregoing approved
treatments in favour of investigational therapy. It will also be
instructive to confirm the idea that like KRAS mutations, those in
BRAF and PIK3CA also predict for lack of clinical benefit from
EGFR mAb therapy.
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